Chronic vasodilator therapy with flosequinan in <font color="red">congestive_1</font> <font color="red">heart_1</font> <font color="red">failure_1</font> <font color="red">._1</font> 
<br>
<br> This study was conducted to determine the <font color="red">long_1</font> <font color="red">-_1</font> <font color="red">term_1</font> <font color="red">effect_1</font> <font color="red">of_1</font> <font color="red">flosequinan_1</font> <font color="red">,_1</font> a new orally administered arterial and venous dilator , on the clinical course of patients with <font color="red">moderate_1</font> <font color="red">to_1</font> <font color="red">severe_1</font> <font color="red">congestive_1</font> <font color="red">heart_1</font> <font color="red">failure_1</font> <font color="red">._1</font> Seventeen patients on chronic digitalis and diuretic therapy were randomized to receive either flosequinan ( n = 9 ) or placebo ( n = 8) in a double - blind fashion . <font color="red">Changes_1</font> <font color="red">in_1</font> <font color="red">symptomatology_4</font> <font color="red">,_4</font> <font color="red">exercise_4</font> <font color="red">performance_4</font> <font color="red">,_4</font> <font color="red">and_2</font> <font color="red">left_4</font> <font color="red">ventricular_4</font> <font color="red">function_4</font> were assessed serially during the two - month treatment period . During the course of therapy , a <font color="red">modest_1</font> <font color="red">improvement_1</font> in the <font color="red">symptom_4</font> <font color="red">scores_4</font> <font color="red">and_2</font> <font color="red">functional_3</font> <font color="red">classification_3</font> of the flosequinan - treated patients was observed . Flosequinan evoked a <font color="red">significant_1</font> <font color="red">increase_1</font> in <font color="red">maximal_6</font> <font color="red">exercise_6</font> <font color="red">capacity_6</font> <font color="red">._6</font> While long - term flosequinan administration also effected a <font color="red">progressive_1</font> <font color="red">increase_2</font> <font color="red">in_1</font> <font color="red">resting_7</font> <font color="red">heart_7</font> <font color="red">rate_7</font> <font color="red">,_7</font> it <font color="red">did_1</font> <font color="red">not_1</font> <font color="red">consistently_1</font> <font color="red">improve_1</font> indices of <font color="red">left_4</font> <font color="red">ventricular_4</font> <font color="red">systolic_4</font> <font color="red">function_4</font> <font color="red">._4</font> The addition of chronic vasodilator therapy with flosequinan to standard digitalis - diuretic regimens is capable of <font color="red">inducing_1</font> <font color="red">clinical_2</font> <font color="red">improvement_2</font> in patients with moderate to severe chronic heart failure . Trials involving larger patient populations will be necessary to confirm the results of this preliminary study and to determine the extent of <font color="red">clinical_1</font> <font color="red">improvement_1</font> <font color="red">,_1</font> subpopulations benefited , role in heart failure therapeutics , and so forth .